13th Semi-Annual Diagnostic Coverage and Reimbursement Conference

December 6-7, 2018 | Boston, MA
Hilton Back Bay
Download Agenda

WE GUARANTEE 100% PRIVACY, YOUR INFORMATION WILL NOT BE SHARED

“I thought the conference was excellent!  Having a conference tailored to one discipline made each panel and contact relevant.”

Director, Compliance & Legal Affairs
Orexigen

“Great insight to hear payer perspective in contracting and account management and the changing healthcare landscape.”

Channel Liaison
Biogen

“It was definitely an excellent well-rounded opportunity to meet new people, get new ideas, and get an in-depth education on what’s to come with the FDA collaborations.”

Quality Engineer
Centurion Medical Products

“It was very well organized event and high quality, the fact to have an IVD track was also interesting. Thanks, I will recommend the Q1 event!”

Regulatory Affairs – EMEA Regional Head
BIOMERIEUX

“The organization and support staff were fantastic! I’m looking forward to next year.”

Global Business Project Lead
Genentech

About the Conference:

Within the rapidly evolving healthcare market, test developers and laboratories face unique challenges in obtaining reimbursement for new diagnostics as payers’ focus increasingly shifts towards cost-efficiency as a priority, in addition to optimized patient outcomes. The necessity to prove value in direct relation to a specific health condition’s market economics is more important than ever before, implying robust evidence not only of scientific benefits but also optimized cost-savings. In the effort of continuously developing evidence-targeted reimbursement strategies, ensuring a clear understanding of Laboratory Benefit Managers’ role is also pivotal to maximize chances of positive decisions and satisfactory coverage. The 13th Semi-Annual Q1 Diagnostic Coverage & Reimbursement Conference will once more dive deep into a variety of pressing matters, also including updated insight into policies such as PAMA entering the new consultation period, how to access NCDs as well as a comprehensive approach to value-based agreements with payers.

Payer Perspectives Including:

  • Scott Flinn of Blue Shield of California
  • Kenneth J. Snow of Aetna
  • Eugean Jiwanmall of Independence Blue Cross
  • Mitchell I. Burken of Evicore Healthcare

Topics Being Addressed Include:

  • Payer Perspectives on Diagnostic Reimbursement Requirements
  • Interpretation of LBM Programs Ensuring Maximized Coverage
  • Proactive Strategies to Combat Downward Reimbursement Pressure
  • Analysis of Government Policy Updates & Impact on Dx Coverage
  • Impact of Value Based Agreements on the Diagnostic Market
  • Test Specific Discussions on NGS, Molecular, CDx & LDTs

Audience

75 Attendees

All attendees come directly from laboratories and diagnostic companies

Distinguished Presenters

27 Speakers

with an average of 15 years experience

Networking

Networking time is built into the agenda to allow industry peers to connect and exchange ideas

Open Dialogue and Group Share

Each presentation is followed by 10-15 minutes of open dialogue for questions and exchange of best practices

Share This